Vorinostat and Concurrent Whole Brain Radiotherapy for Brain Metastasis

Summary

Vorinostat is a potent and well tolerated HDAC inhibitor. It has been reported to enhance radiosensitivity of cancer cells. We hypothesize that the addition of vorinostat to WBRT may increase therapeutic efficacy for patients with brain metastases.

Timeline

Start

2012-08

Primary completion

2013-12

Completion

2013-12

Outcome

Outcome not reported

Stopped: “Sponsor stops to provide the study drug.”

Drugs

Indications